| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Natural Sesquiterpene
β-Bisabolene does not have a defined biological target but exhibits anticancer activity. It induces apoptosis in breast cancer cell lines, including MCF-10A, MDA-MB-231, and BT474 cells. β-Bisabolene may induce apoptosis in the A549 cancer cell line. It also exhibits anti-inflammatory, antimicrobial, and anticancer properties. The compound's mechanism of action involves the induction of apoptosis in cancer cells. |
|---|---|
| ln Vitro |
β-Bisabolene demonstrates specific cytotoxic action on mouse cells, exhibiting IC50 values of >200 µg/ml, 65.49 µg/ml, and 48.99 µg/ml against normal Eph4, MG1361, and 4T1 cells, respectively. With IC50 values of 114.3 µg/mL, 66.91 µg/mL, 98.39 µg/mL, 70.62 µg/mL, and 74.3 µg/mL, respectively, against normal MCF-10A, MCF-7, MDA-MB-231, SKBR3, and BT474 cells[1].
In vitro, β-bisabolene exhibits cytotoxicity towards breast cancer cell lines, inducing apoptosis in MCF-10A, MDA-MB-231, and BT474 cells. It shows selective cytotoxicity for mouse cells. β-Bisabolene may induce apoptosis in the A549 cancer cell line. It has been studied for its potential anti-inflammatory, antimicrobial, and anticancer properties. The compound also serves as a precursor to the advanced biofuel bisabolane. |
| ln Vivo |
β-Bisabolene is successful in stopping the in vivo growth of transplanted 4T1 mammary tumors (37.5% reduction in volume by endpoint)[1].
In vivo, β-bisabolene has been shown to reduce tumor volume by 37.5% at the experimental endpoint in breast cancer models. It exhibits anticancer activity and has been studied for its potential in treating breast cancer. The compound has not been evaluated in clinical trials and is not approved for therapeutic use. β-Bisabolene is a research compound used to study cancer and inflammation. |
| Enzyme Assay |
Gas chromatography-mass spectrometry (GC-MS) analysis[1]
Opoponax extracts were analysed using a Finnegan GC 8000 gas chromatograph equipped with a MD 800 mass selective detector and an AS800 Finnegan autosampler. For the capillary column, a DB-5 fused silica column was used with the following dimensions: 30 × 0.32 mm id and 0.25-µm film thickness. The temperature of the oven was programmed from 50 to 240 °C at a rate of 3 °C/min and maintained at this final temperature for 2 min. The helium carrier gas was set at a flow rate set of 1 ml/min, maintained under constant pressure, while the injector and source temperatures were both set at 260 °C. The mass detector was used in the positive electron impact ionization mode (EI+) using an ionization voltage of 70 eV. A scan range of 35 to 450 mass units in 0.45 s was used for acquiring mass spectra with an interscan time of 0.08 s. In vitro assays for β-bisabolene typically involve cell viability and proliferation assays. A standard protocol involves culturing breast cancer cells (e.g., MDA-MB-231, MCF-7) in 96-well plates and treating them with varying concentrations of β-bisabolene (typically 1-100 µM) for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. Apoptosis is measured using Annexin V/PI staining or caspase activity assays. IC₅₀ values are calculated from dose-response curves. |
| Cell Assay |
Cell viability assay[1]
For viability assays, murine cells were plated at a density of 10 000 cells/well and human cells were plated at 20 000 cells/well into a 96-well plate. Cells were treated 24 h after seeding with respective agents prepared in the media. The viability of cells in each well was then quantified using Cell Titer Blue according to the manufacturer's instructions 24 h after treatment. Apoptosis assays[1] Cell lysates after specified treatments were analysed with Caspase Glo 3/7 Assay Kit according to the manufacturer's instructions. Annexin-V/propidium iodide (PI) analysis was performed using Dead Cell Apoptosis Kit according to the manufacturer's instructions, and stained cells were analysed using a BD FACSCanto flow cytometer. In vitro cell culture experiments with β-bisabolene typically involve breast cancer cell lines such as MCF-10A, MDA-MB-231, and BT474. Cells are cultured in appropriate media and treated with the compound at concentrations ranging from 1-100 µM for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. Apoptosis is measured using Annexin V/PI staining or caspase activity assays. |
| Animal Protocol |
In vivo administration of β-bisabolene[1]
Of the oily compound β-bisabolene, solubilized in corn oil, 1.12 g/kg was administered intraperitoneally, two times a week, for 2 weeks, did not result in any signs of distress in all animals. Upon necropsy, the histology of liver, kidney, spleen and lung of these mice appeared normal (data not shown). When a dose of 2.24 g/kg was administered, mice showed signs of morbidity after single treatment. Hence, we used a maximum non-lethal dose of 1.12 g/kg β-bisabolene in our tumour growth studies. The treatment regime consisted of intraperitoneal (i.p.) injections twice weekly, once palpable tumour was detected (at 2 weeks) and until mice have reached the endpoint of the experiment or showed signs of morbidity. Orthotopic cell transplants and tumour measurements[1] All animal experiments were conducted in accordance with the UK Animals Act 1986, under Home Office licence 30/2849. 4T1 cells were trypsinized and dissociated into single-cell suspensions before transplantation into the abdominal mammary fat pads of wild-type BALB/C mice that were between 8 and 12 weeks old. Mice were then checked for palpable tumours, and the resulting tumours were measured using calipers three times weekly. At appropriate experimental endpoints, tumour, mammary gland, lung and liver tissues were harvested. Tissue samples were then fixed in 4% formaldehyde at 4 °C overnight before processing for histological analysis. Immunohistology[1] Fixed tissues were embedded in paraffin, sectioned into 5-µm slices, mounted onto poly-L-lysine-coated slides and stained with haematoxylin and eosin. Antibodies for cleaved caspase-3 and Ki-67 (Vector Labs) were used for immunohistology according to the manufacturer's instructions. In vivo animal studies with β-bisabolene are conducted to study its anticancer effects. A typical protocol involves administering the compound orally or intraperitoneally to mice bearing breast cancer xenografts at doses ranging from 10-100 mg/kg. Tumor volume is measured twice weekly. β-Bisabolene has been shown to reduce tumor volume by 37.5% at the experimental endpoint. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of β-bisabolene are not characterized, as it is not a drug substance. Based on its physicochemical properties (molecular weight 204.35, lipophilic hydrocarbon), the compound would be expected to have good oral bioavailability. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
β-Bisabolene is generally considered to have low toxicity. Standard laboratory precautions should be followed when handling the compound, including the use of gloves and safety glasses. The compound should be stored in a cool, dry place away from light and moisture. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| References | |
| Additional Infomation |
(S)-β-bisabolene is a β-bisabolene with a (1S) configuration, and it is the enantiomer of (R)-β-bisabolene. β-bisabolene has been reported to exist in Magnolia officinalis, Citronella foenum-graecum, and other organisms with relevant data.
β-Bisabolene is a monocyclic sesquiterpene isolated from opoponax (Commiphora guidotti). It exhibits selective cytotoxicity towards breast cancer cell lines and synergistic antibacterial activity. β-Bisabolene has been studied for its potential anti-inflammatory, antimicrobial, and anticancer properties. It has not undergone clinical trials and is not approved as a pharmaceutical. |
| Molecular Formula |
C15H24
|
|---|---|
| Molecular Weight |
204.35
|
| Exact Mass |
204.188
|
| CAS # |
495-61-4
|
| PubChem CID |
10104370
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.854g/cm3
|
| Boiling Point |
275.441ºC at 760 mmHg
|
| Flash Point |
109.79ºC
|
| Vapour Pressure |
0.009mmHg at 25°C
|
| Index of Refraction |
1.484
|
| LogP |
5.035
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
274
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[#6]\[#6](-[#6])=[#6]\[#6]-[#6]-[#6](=[#6])-[#6]-1-[#6]-[#6]-[#6](-[#6])=[#6]-[#6]-1 |c:12|
|
| InChi Key |
XZRVRYFILCSYSP-OAHLLOKOSA-N
|
| InChi Code |
InChI=1S/C15H24/c1-12(2)6-5-7-14(4)15-10-8-13(3)9-11-15/h6,8,15H,4-5,7,9-11H2,1-3H3/t15-/m1/s1
|
| Chemical Name |
(4S)-1-methyl-4-(6-methylhepta-1,5-dien-2-yl)cyclohexene
|
| Synonyms |
β-Bisabolene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (489.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8936 mL | 24.4678 mL | 48.9356 mL | |
| 5 mM | 0.9787 mL | 4.8936 mL | 9.7871 mL | |
| 10 mM | 0.4894 mL | 2.4468 mL | 4.8936 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA